News
ONTXW
--
0.00%
--
BRIEF-Onconova Therapeutics Reports Encouraging Data For Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer
reuters.com · 23h ago
BRIEF-Onconova Therapeutics Reports Second Quarter 2021 Financial Results
reuters.com · 08/12 21:53
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2021 Financial Results on August 12, 2021
Company to host conference call and webcast at 4:30 p.m. ET on Thursday, August 12.NEWTOWN, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering an...
GlobeNewswire · 08/05 12:00
BRIEF-Onconova Therapeutics Regains Compliance With Nasdaq Continued Listing Requirement
reuters.com · 06/22 12:50
BRIEF-Onconova Therapeutics Announces The Initial Dosing Of The First Patient In The U.S. Phase 1 Clinical Trial Of On 123300
reuters.com · 05/21 12:05
BRIEF-Onconova Therapeutics Announces Reverse Stock Split And Decrease In Authorized Shares
reuters.com · 05/20 12:45
BRIEF-Onconova Therapeutics Inc - Received Letter From Nasdaq Indicating Co Failed To Comply With Minimum Bid Price Requirement Of Nasdaq Listing Rule
reuters.com · 05/14 12:09
BRIEF-Onconova Announces First Patient Dosed In Investigator-Initiated Phase 2 Study Of Rigosertib In Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma
reuters.com · 04/22 12:22
BRIEF-Onconova Therapeutics Announces Enrollment In Second Cohort Of Phase 1 Study With On 123300 In China
reuters.com · 04/01 13:03
BRIEF-Onconova Therapeutics Inc Announces Pricing Of $25 Million Public Offering Of Common Stock
reuters.com · 02/11 03:51
BRIEF-Onconova Therapeutics, Inc. Announces Proposed Public Offering Of Common Stock
reuters.com · 02/10 21:16
BRIEF-Onconova Therapeutics Says Compensation Committee Approved A Cash Bonus Program Of Cash-Settled SAR And Cash-Settled PSU To Employees
* ONCONOVA THERAPEUTICS INC - COMPENSATION COMMITTEE APPROVED A CASH BONUS PROGRAM OF CASH-SETTLED SAR AND CASH-SETTLED PSU TO EMPLOYEES Source text: [https://bit.ly/2CokShr] Further company coverage: (Reuters.Briefs@thomsonreuters.com)
Reuters · 07/10/2020 21:30
BRIEF-Onconova Therapeutics Announces The Initiation Of A Phase 1/2A Study Of Rigosertib Plus Nivolumab For The Treatment Of Kras+ Lung Adenocarcinoma
* ONCONOVA THERAPEUTICS ANNOUNCES THE INITIATION OF A PHASE 1/2A STUDY OF RIGOSERTIB PLUS NIVOLUMAB FOR THE TREATMENT OF KRAS+ LUNG ADENOCARCINOMA Source text for Eikon: Further company coverage:
Reuters · 06/22/2020 12:48
BRIEF-Onconova Therapeutics Files For Potential Mixed Shelf Offering Of Up To $150 Million
* ONCONOVA THERAPEUTICS FILES FOR POTENTIAL MIXED SHELF OFFERING OF UP TO $150 MILLION - SEC FILING Source text: (https://bit.ly/3fQVVdD) Further company coverage:
Reuters · 05/15/2020 21:26
Webull provides a variety of real-time ONTXW stock news. You can receive the latest news about ONCONOVA THERAPE through multiple platforms. This information may help you make smarter investment decisions.
About ONTXW
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.